PMID- 28836498
OWN - NLM
STAT- MEDLINE
DCOM- 20171124
LR  - 20171128
IS  - 0231-5882 (Print)
IS  - 0231-5882 (Linking)
VI  - 36
IP  - 4
DP  - 2017 Oct
TI  - Evaluation of liposomal carnosine in adjuvant arthritis.
PG  - 471-479
LID - 10.4149/gpb_2017014 [doi]
AB  - Liposomal carnosine could overcome the problems associated with direct 
      application of this peptide. Anti-inflammatory and antioxidant effects of 
      liposomal and non-liposomal carnosine in adjuvant arthritis were compared. The 
      experiments were done on healthy animals, untreated arthritic animals, arthritic 
      animals with oral administration of carnosine, and with subcutaneous 
      administration of liposomal carnosine, both administered in the same daily dose 
      of 150 mg/kg b.w. during 28 days. Carnosine reduced hind paw volume on day 28. 
      Both forms markedly decreased interleukin-1beta, matrix metalloproteinase-9 and 
      monocyte chemoattractant protein-1 (MCP-1) in plasma on day 14. Only liposomal 
      carnosine reduced significantly MCP-1. Malondialdehyde, 4-hydroxynonenal, 
      resistance to Fe2+-induced oxidation and protein carbonyls were significantly 
      corrected after administration of any form of carnosine. Liposomal carnosine 
      corrected more effectively the oxidative stress in plasma than did carnosine. In 
      brain tissue, our results showed protective ability of both forms of carnosine 
      against oxidation of proteins and lipids. They also corrected the resistance to 
      Fe2+-induced oxidation in arthritic animals. We found that only liposomal 
      carnosine decreased the mRNA expression of inducible nitric oxide synthase in 
      cartilage tissue. It can be concluded that the liposomal drug-delivery system is 
      improving the pharmacological properties of carnosine administered in arthritis.
FAU - Slovak, Lukas
AU  - Slovak L
AD  - Institute of Experimental Pharmacology and Toxicology of the Slovak Academy of 
      Sciences, Dubravska cesta 9, Bratislava, Slovakia. katarina.bauerova@savba.sk.
FAU - Ponist, Silvester
AU  - Ponist S
FAU - Fedorova, Tatiana
AU  - Fedorova T
FAU - Logvinenko, Anna
AU  - Logvinenko A
FAU - Levacheva, Irina
AU  - Levacheva I
FAU - Samsonova, Olga
AU  - Samsonova O
FAU - Bakowsky, Udo
AU  - Bakowsky U
FAU - Paskova, Ludmila
AU  - Paskova L
FAU - Cavojsky, Tomas
AU  - Cavojsky T
FAU - Tsiklauri, Lia
AU  - Tsiklauri L
FAU - Bauerova, Katarina
AU  - Bauerova K
LA  - eng
PT  - Journal Article
DEP - 20170824
PL  - Slovakia
TA  - Gen Physiol Biophys
JT  - General physiology and biophysics
JID - 8400604
RN  - 0 (Cytokines)
RN  - 0 (Liposomes)
RN  - 8HO6PVN24W (Carnosine)
RN  - 9007-81-2 (Freund's Adjuvant)
SB  - IM
MH  - Animals
MH  - Arthritis/chemically induced/*drug therapy/*immunology
MH  - Carnosine/*administration & dosage/chemistry
MH  - Cytokines/*immunology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Freund's Adjuvant
MH  - Liposomes
MH  - Oxidative Stress/drug effects/immunology
MH  - Treatment Outcome
EDAT- 2017/08/25 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/08/25 06:00
PHST- 2017/03/08 00:00 [received]
PHST- 2017/04/03 00:00 [accepted]
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
AID - 10.4149/gpb_2017014 [doi]
PST - ppublish
SO  - Gen Physiol Biophys. 2017 Oct;36(4):471-479. doi: 10.4149/gpb_2017014. Epub 2017 
      Aug 24.